Cynthia Moylan

Article Type

Article

Changed

Mon, 04/21/2025 - 13:32

Display Headline

HCC Updates: Quality Care Framework and Risk Stratification Data

Author(s)

Janice Jou, MD, MHS

Cynthia Moylan

Click here to view more from Cancer Data Trends 2025.

References

1. Rogal SS, Taddei TH, Monto A, et al. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project. Clin Gastroenterol Hepatol. 2024 Feb;22(2):324-338. doi:10.1016/j.cgh.2023.07.002

2. John BV, Dang Y, Kaplan DE, et al. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2024 Apr;22(4):778-788.e7. doi:10.1016/j.cgh.2023.11.020

Author and Disclosure Information

Janice H. Jou, MD, MHS
Section Chief, Division of Gastroenterology
VA Portland Healthcare System
Portland, Oregon
Disclosures: Received research grant from: Gilead

Cynthia A. Moylan, MD, MHS
Associate Professor of Medicine
Director of Hepatology
Durham VA Medical Center;
Co-Director of GI-HEP Clinical Research Unit, Division of Gastroenterology
Duke University Medical Center
Durham, North Carolina
Disclosures: Received research grant from: GSK; Madrigal; Exact Sciences.
Received income in an amount equal to or greater than $250 from: Novo Nordisk; Sirtex; Boehringer Ingelheim.

Publications

Federal Practitioner

Topics

Hepatocellular Carcinoma

Oncology

Read more about HCC Updates: Quality Care Framework and Risk Stratification Data

Author(s)

Author(s)

Author and Disclosure Information

Janice H. Jou, MD, MHS
Section Chief, Division of Gastroenterology
VA Portland Healthcare System
Portland, Oregon
Disclosures: Received research grant from: Gilead

Cynthia A. Moylan, MD, MHS
Associate Professor of Medicine
Director of Hepatology
Durham VA Medical Center;
Co-Director of GI-HEP Clinical Research Unit, Division of Gastroenterology
Duke University Medical Center
Durham, North Carolina
Disclosures: Received research grant from: GSK; Madrigal; Exact Sciences.
Received income in an amount equal to or greater than $250 from: Novo Nordisk; Sirtex; Boehringer Ingelheim.

Author and Disclosure Information

Janice H. Jou, MD, MHS
Section Chief, Division of Gastroenterology
VA Portland Healthcare System
Portland, Oregon
Disclosures: Received research grant from: Gilead

Cynthia A. Moylan, MD, MHS
Associate Professor of Medicine
Director of Hepatology
Durham VA Medical Center;
Co-Director of GI-HEP Clinical Research Unit, Division of Gastroenterology
Duke University Medical Center
Durham, North Carolina
Disclosures: Received research grant from: GSK; Madrigal; Exact Sciences.
Received income in an amount equal to or greater than $250 from: Novo Nordisk; Sirtex; Boehringer Ingelheim.

Click here to view more from Cancer Data Trends 2025.

References

1. Rogal SS, Taddei TH, Monto A, et al. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project. Clin Gastroenterol Hepatol. 2024 Feb;22(2):324-338. doi:10.1016/j.cgh.2023.07.002

2. John BV, Dang Y, Kaplan DE, et al. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2024 Apr;22(4):778-788.e7. doi:10.1016/j.cgh.2023.11.020

References

1. Rogal SS, Taddei TH, Monto A, et al. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project. Clin Gastroenterol Hepatol. 2024 Feb;22(2):324-338. doi:10.1016/j.cgh.2023.07.002

2. John BV, Dang Y, Kaplan DE, et al. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2024 Apr;22(4):778-788.e7. doi:10.1016/j.cgh.2023.11.020

Publications

Federal Practitioner

Publications

Federal Practitioner

Topics

Hepatocellular Carcinoma

Oncology

Article Type

Article

Display Headline

HCC Updates: Quality Care Framework and Risk Stratification Data

Display Headline

HCC Updates: Quality Care Framework and Risk Stratification Data

Disallow All Ads

Content Gating

No Gating (article Unlocked/Free)

Alternative CME

Disqus Comments

Default

Eyebrow Default

SLIDESHOW

Gate On Date

Sun, 04/06/2025 - 18:23

Un-Gate On Date

Sun, 04/06/2025 - 18:23

Consolidated Pubs: Do Not Show Source Publication Logo

Use ProPublica

CFC Schedule Remove Status

Sun, 04/06/2025 - 18:23

Conference Recap Checkbox

Not Conference Recap

Clinical Edge

Display the Slideshow in this Article

Article Slideshow Optional Introduction

The VA National Gastroenterology and Hepatology Program, the largest provider of cirrhosis care in the United States, recently examined factors related to hepatocellular carcinoma (HCC) diagnosis stage, treatment options, and patient survival in veterans in a retrospective study.¹The results emphasize the value of HCC screening and continuous patient engagement for improving diagnosis, treatment, and survival outcomes for veterans. They also demonstrate the practicality of creating a national quality improvement framework for HCC screening, diagnosis, and care.¹

Veterans with cirrhosis due to chronic hepatitis C virus (HCV) remain at risk for HCC, even after achieving a sustained virological response (SVR). A 2024 retrospective cohort study of veterans with HCV-related cirrhosis concluded that liver stiffness measurement post-SVR could help stratify HCC risk.²These data highlight the importance of ongoing HCC screening and active patient engagement to improve survival and, ultimately, quality of life for veterans living with this condition.

Medscape Article

Display survey writer

Reuters content

Disable Inline Native ads

WebMD Article

survey writer start date

Sun, 04/06/2025 - 18:23

Slide Media

User login

HCC Updates: Quality Care Framework and Risk Stratification Data